Agios Pharmaceuticals, Inc. (AGIO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-87.2%

$3.85

vs $29.95 price

Levered DCF

-$57.22

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

11.59

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-3.82×	2.77×	-3.52×	-6.64×	-5.17×	-9.14×	-7.22×	-7.65×
P/B	1.32×	1.21×	1.53×	1.4×	1.54×	7.48×	4.47×	3.85×
P/S	29.21×	51.14×	46.21×	108.04×	0×	0×	24.3×	28.05×
EV / EBITDA	-3.74×	2.55×	-3.54×	-6.65×	-5.42×	-9.56×	-7.18×	-5.44×
Gross margin	78.7%	88.6%	64.6%	88.0%	0.0%	0.0%	98.9%	98.5%
Operating margin	-873.9%	-1166.5%	-1459.5%	-2732.1%	0.0%	0.0%	-361.6%	-384.0%
Net margin	-764.0%	1845.9%	-1312.6%	-1627.8%	0.0%	0.0%	-349.0%	-366.6%
Current ratio	11.46×	11.9×	12.27×	13.3×	17.79×	6.74×	6.59×	6.56×
Debt / equity	0.03×	0.04×	0.09×	0.08×	0.08×	0.26×	0.18×	0×
Interest coverage	0×	0×	0×	0×	0×	-18.84×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-34.6%	43.7%	-43.4%	-21.1%	124.2%	-81.9%	-64.2%	-50.3%
Return on invested capital	-38.2%	-25.0%	-44.3%	-32.7%	-27.2%	-43.9%	-53.0%	-47.4%
Return on assets	-31.8%	40.5%	-37.6%	-18.7%	111.6%	-38.4%	-46.2%	-40.3%
Free cash flow yield	-23.9%	-21.0%	-24.0%	-20.4%	-20.8%	-10.2%	-13.4%	-11.8%
Earnings yield	-26.2%	36.1%	-28.4%	-15.1%	80.8%	-11.0%	-14.4%	-13.1%
Enterprise value	$1.5B	$1.8B	$1.2B	$1.5B	$1.9B	$3B	$2.9B	$1.8B
Net debt / EBITDA	0.12×	-0.03×	0.05×	0.24×	0.31×	0.07×	-0.08×	2.38×
Cash conversion cycle (days)	533	1,003	395	-2,112	-325	-345	-3,989	-4,404